[HT-15-3] Byond Awaji Criteria
ALS has been a non-curable disease, but its disease-modifying therapy is emerging increasingly. There have been hundreds of promising therapeutic agents tested for its efficacy in animal models, but only few have been approved for humans with limited efficacy. As in Alzheimer's disease, it may not be possible to change its natural course if the regimen is started too late. To this end, the diagnosis of ALS should be made early, and more surviving motor neurons be tested for the efficacy of any agent. One of these criteria for early electrophysiological diagnosis is Awaji-criteria, and its has been shown that the diagnosis is made possible several months earlier compared with Airlie House-El Escorial criteria with similar specificity. Other disease-markers, especially for detecting upper motor neuron involvement, are now being explored. In this talk, the most updated information is reviewed on these measures for early diagnosis, which make it possible to start a potentially effective treatment for disease modification.
1978 Graduate from School of Medicine, University of Tokyo
1978-2007 Department of Neurology, the University of Tokyo
(1987 -1989 under Professor Marsden, Queen Square)
May, 2007- March, 2018 Professor and Chairman, Department of Neurology, FMU
April 2018 Professor and Chairman, Department of Neuro-regeneration, FMU
MEMBERSHIPS
International Federation of Clinical Neurophysiology (IFCN), Secretary general 2014-2017
Movement Disorders Society Asian Oceania Section, Executive committee, treasurer 2013 -
Japanese Society of Neurology executive board member, auditor 2019-
Japanese Society of Clinical Neurophysiology executive board member, auditor 2017-
Movement disorders society, Japan executive board member, President 2015-2017
Past president 2017-
抄録パスワード認証
パスワードは抄録集に記載してあります。